New Blood Test Shows Promise in Early Detection of Severe Liver disease
Stockholm, Sweden - A new, simple blood test utilizing three common measurements could substantially improve early detection of serious liver diseases like cirrhosis adn cancer, according to a study published in the journal BMJ. The test, dubbed CORE, demonstrates a high degree of accuracy in predicting which individuals are at risk of developing these conditions – even before symptoms appear, offering a crucial advantage in treatment outcomes.
researchers at the Karolinska Institute in Sweden, collaborating with colleagues in Finland, analyzed data from over 480,000 individuals who participated in health checks over a 30-year period to develop and validate the CORE model. The model assesses risk based on five factors: age, gender, and the levels of three readily available liver enzymes – AST, ALT, and GGT – typically measured during routine blood work.
The study found CORE to be remarkably accurate, correctly predicting the progress of serious liver disease in 88% of cases over a ten-year period. This surpasses the accuracy of the currently recommended FIB-4 method.
“So far we have lacked a reliable tool to identify people at high risk of liver disease early,” explained study leader Hannes Hagström. “The development of CORE is an critically important step in closing this gap.”
The test is especially valuable for individuals with increased risk factors, including those who are overweight, have type 2 diabetes, or consume high levels of alcohol, as these groups are more prone to developing fatty liver disease.
A key benefit of CORE is its accessibility. Researchers state the test is easily implemented in general practitioner offices and utilizes data already commonly collected. Results from standard blood tests, combined with age and gender data, can be entered into a freely available, web-based computer program at https://www.core-model.com/ for immediate risk assessment,allowing for prompt further inquiry if needed.
Early detection is critical, as the chances of recovery from liver diseases often diminish significantly once symptoms manifest. This new test offers a potentially life-saving tool for proactive healthcare.
